Hung-Wei Chih

Hung-wei Chih currently serves as VP, Head of Pre-Pivotal Biologics Technical Development at Gilead Sciences since March 2023. Prior experience includes leadership roles at Sana Biotechnology, Inc. as VP, Head of Pharmaceutical Development and Cell Therapy Manufacturing from October 2019 to December 2022, and Taiwan Liposome Company as VP, Head of CMC in 2018-2019. Hung-wei Chih spent 13 years at Genentech, progressing from Scientist in Early Stage Pharmaceutical Development to Director, Head of US IMP Product Quality. Earlier positions include Scientist at ImmunoGen, Inc. focusing on Analytical and Formulation Development and Staff Investigator at ArQule, specializing in Assay Development. Hung-wei Chih earned a Ph.D. in Chemistry from the University of Michigan between 1996 and 2001.